Tuesday, January 31, 2023 6:20:33 AM
Millions of children globally are diagnosed with ADHD and/or Autism Spectrum Disorder (ASD), and many of them also suffer from additional mental, emotional, or behavioral conditions. While therapy and medication are commonly prescribed, these drugs can come with side effects such as sleep disturbances, appetite loss, headaches, stomach issues, and mood swings.
To address this unmet need for a natural and holistic treatment for neurocognitive disorders, Regencell is conducting efficacy trials on its standardized Traditional Chinese Medicine (TCM) formulae.
Regencell's TCM Formulae
Regencell's TCM formulae are all-natural liquid TCM treatments for ADHD and ASD. In its latest trial, the formulae were given to children twice daily for three months.
Developed by a TCM practitioner based on the Sik-Kee Au TCM Brain Theory®, the formulae contain only natural ingredients and have been used for over 30 years to treat a range of neurological illnesses and disorders, including ADHD and ASD, with positive results.
According to the TCM brain theory, disruptions in blood flow and damage to the central nervous, endocrine, and circulatory systems can impact the production of hormones and transmission of neurotransmitters like melatonin, dopamine, and norepinephrine. This results in poor encoding and decoding of functions, causing the social behaviors characteristic of ADHD and ASD.
Regencell Bioscience Holdings is an early-stage company focused on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders, including ADHD and ASD, and infectious diseases like COVID-19. The company has already completed a study on personalized TCM formulae for ADHD and ASD in Hong Kong and plans to launch three liquid-based TCM formulae for mild, moderate, and severe cases of ADHD and ASD, starting in Hong Kong and expanding to other markets as appropriate. Regencell has also formed a joint venture to offer COVID-19 treatments in various countries in Asia, India, Japan, Australia, and New Zealand. For more information, visit their websites at www.regencellbioscience.com and www.regencellasia.com.
Recent RGC News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/02/2024 11:04:03 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/15/2023 11:09:52 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/27/2023 08:15:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM